Prostate Cancer - Results from #1220

The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer. March 14, 2024

Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials. March 14, 2024

Identifying low cancer-specific mortality risk lymph node-positive radical prostatectomy patients. March 14, 2024

A Comprehensive National Survey of Prostate-specific Antigen Testing and Prostate Cancer Management in France: Uncovering Regional and Temporal Disparities. March 14, 2024

A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening. March 14, 2024

Influence of early apical release on outcomes in endoscopic enucleation of the prostate: results from a multicenter series of 4392 patients. March 13, 2024

Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P). March 13, 2024

Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict Prostate Cancer Risk. March 13, 2024

Evaluating Diagnostic Accuracy and Inter-reader Agreement of the Prostate Imaging After Focal Ablation Scoring System. March 13, 2024

Defining the challenges and opportunities for using patient-derived models in prostate cancer research. March 13, 2024

Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system. March 13, 2024

Prediagnostic Prostate-specific Antigen Testing and Clinical Characteristics in Men with Lethal Prostate Cancer. March 13, 2024

Dietary interventions in cancer: a systematic review of all randomized controlled trials. March 13, 2024

Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH. March 12, 2024

Major Complications and Adverse Events Related to Use of SpaceOAR Hydrogel for Prostate Cancer Radiotherapy. March 12, 2024

Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era. March 12, 2024

Canonical AREs are tumor suppressive regulatory elements in the prostate. March 12, 2024

Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study. March 12, 2024

TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. March 11, 2024

Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. March 11, 2024

Page 62 of 1436